The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Results from the Phase II ELM-2 trial: odronextamab for R/R follicular lymphoma
Stefano Luminari, MD, University of Modena and Reggio Emilia, Modena, Italy, discusses results from the Phase II ELM-2 trial (NCT03888105), which is assessing the safety and efficacy of odronextamab in patients with relapsed/refractory (R/R) grade 1-3A follicular lymphoma (FL). Dr Luminari highlights the progression-free survival (PFS) and overall response rate (ORR) observed, and further comments on the activity and safety of this agent. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Roche: Consultancy; Janssen: Consultancy; Gilead/Kite: Consultancy; BMS/Celgene: Consultancy; Regeneron: Consultancy; Genmab: Consultancy.
